# OnCo record gsk2256098 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/gsk2256098/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "gsk2256098" ;
  schema:name "GSK2256098"@en ;
  schema:alternateName "GSK-2256098"@en ;
  schema:description "GSK2256098 is a tablet that blocks an enzyme called FAK, which meningiomas missing the NF2 gene rely on. In the Alliance A071401 trial it slowed progression in recurrent NF2-mutant meningiomas, one of the first positive results for a targeted drug in this tumour."@en ;
  schema:url <https://onco.cc/drugs/gsk2256098/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.21.02371>, <https://clinicaltrials.gov/study/NCT02523014> ;
  onco:status "phase-2" ;
  onco:tag "subtype-drugs-wave" ;
  onco:modality "Oral focal adhesion kinase (FAK) inhibitor" ;
  onco:cancers <https://onco.cc/cancers/meningioma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/fak/> ;
  onco:companies <https://onco.cc/companies/gsk/> ;
  onco:trials <https://onco.cc/trials/a071401/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-a071401-brastianos-jco-2023/> .